Overview
- DRAP said prices of essential medicines, including insulin, have not been raised.
- The figures cited in reports were Maximum Retail Prices printed on 2024–2025 batches, not new approvals.
- Manufacturers are barred from unilateral increases on products listed on the National Essential Medicines List.
- The regulator said it is tracking availability and found supply conditions satisfactory for the coming months.
- DRAP issued advisories urging contingency plans and multiple sourcing to prevent future shortages.